AZD4512 monotherapy(AstraZeneca)은 B-cell Acute Lymphoblastic Leukemia (B-A 표적 ADC로, B-cell Acute Lymphoblastic Leukemia (B-ALL) 영역에서 개발·상용화 중입니다. 작용기전: target FGF-2 and its receptors, inactivating the FGF-2/FGFR1/2 pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 2건의 관련 임상이 등록되어 있습니다. 차별점: novel pH-responsive nanoreactor for pyroptosis induction: multifaceted ROS amplification drives potent immunotherapy against.
B-cell Acute Lymphoblastic Leukemia (B-A
B-cell Acute Lymphoblastic Leukemia (B-ALL)
Recruiting
ADC) was associated with the largest estimated improvements in
humanized PD1 +/+ mice
novel pH-responsive nanoreactor for pyroptosis induction: multifaceted ROS amplification drives potent immunotherapy against
target FGF-2 and its receptors, inactivating the FGF-2/FGFR1/2 pathway
macrophages from the M1 to M2 phenotype, suppress fibroblast-like synoviocyte activation
DNA damage response (DDR) mutations and circulating tumor DNA (ctDNA) clearance emerged as promising biomarkers
biomarker-informed trials, rather than to identify a single preferred ICI strategy
resistance to current treatment strategies indicates the need for more effective agents to treat lung adenocarcinoma (LUAD)
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
AZD4512 monotherapy(AstraZeneca)은 B-cell Acute Lymphoblastic Leukemia (B-A 표적 ADC로, B-cell Acute Lymphoblastic Leukemia (B-ALL) 영역에서 개발·상용화 중입니다. 작용기전: target FGF-2 and its receptors, inactivating the FGF-2/FGFR1/2 pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 2건의 관련 임상이 등록되어 있습니다. 차별점: novel pH-responsive nanoreactor for pyroptosis induction: multifaceted ROS amplification drives potent immunotherapy against.
B-cell Acute Lymphoblastic Leukemia (B-A
B-cell Acute Lymphoblastic Leukemia (B-ALL)
Recruiting
ADC) was associated with the largest estimated improvements in
humanized PD1 +/+ mice
novel pH-responsive nanoreactor for pyroptosis induction: multifaceted ROS amplification drives potent immunotherapy against
target FGF-2 and its receptors, inactivating the FGF-2/FGFR1/2 pathway
macrophages from the M1 to M2 phenotype, suppress fibroblast-like synoviocyte activation
DNA damage response (DDR) mutations and circulating tumor DNA (ctDNA) clearance emerged as promising biomarkers
biomarker-informed trials, rather than to identify a single preferred ICI strategy
resistance to current treatment strategies indicates the need for more effective agents to treat lung adenocarcinoma (LUAD)
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.